Etoricoxib-Cannabidiol Combo: Potential Role in Glioblastoma Treatment and Development of PLGA-Based Nanoparticles
-
Published:2023-08-09
Issue:8
Volume:15
Page:2104
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Kuźmińska Joanna12, Sobczak Agnieszka1ORCID, Majchrzak-Celińska Aleksandra3ORCID, Żółnowska Izabela1, Gostyńska Aleksandra1ORCID, Jadach Barbara4ORCID, Krajka-Kuźniak Violetta3ORCID, Jelińska Anna1, Stawny Maciej1ORCID
Affiliation:
1. Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland 2. Doctoral School, Poznan University of Medical Sciences, Bukowska 70, 60-812 Poznań, Poland 3. Chair and Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Święcickiego 4, 60-781 Poznań, Poland 4. Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland
Abstract
Background: Glioblastoma (GBM) is the most frequently occurring primary malignant central nervous system tumor, with a poor prognosis and median survival below two years. Administration of a combination of non-steroidal anti-inflammatory drugs and natural compounds that exhibit a curative or prophylactic effect in cancer is a new approach to GBM treatment. This study aimed to investigate the synergistic antitumor activity of etoricoxib (ETO) and cannabidiol (CBD) in a GBM cell line model, and to develop poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs) for these two substances. Methods: The activity of ETO+CBD was determined using the MTT test, cell-cycle distribution assay, and apoptosis analysis using two GBM cell lines, namely, T98G and U-138 MG. The PLGA-based NPs were developed using the emulsification and solvent evaporation method. Their physicochemical properties, such as shape, size, entrapment efficiency (EE%), in vitro drug release, and quality attributes, were determined using scanning electron microscopy, diffraction light scattering, high-performance liquid chromatography, infrared spectroscopy, and differential scanning calorimetry. Results: The combination of ETO and CBD reduced the viability of cells in a dose-dependent manner and induced apoptosis in both tested GBM cell lines. The developed method allowed for the preparation of ETO+CBD-NPs with a spherical shape, mean particle size (MPS) below 400 nm, zeta potential (ZP) values from −11 to −17.4 mV, polydispersity index (PDI) values in the range from 0.029 to 0.256, and sufficient EE% of both drugs (78.43% for CBD, 10.94% for ETO). Conclusions: The combination of ETO and CBD is a promising adjuvant therapeutic in the treatment of GBM, and the prepared ETO+CBD-NPs exhibit a high potential for further pharmaceutical formulation development.
Funder
Poznan University of Medical Sciences
Subject
Pharmaceutical Science
Reference55 articles.
1. Anti-inflammatory agents as cancer therapeutics;Kashfi;Adv. Pharmacol.,2009 2. Anti-Inflammatory Agents for Cancer Therapy;Rayburn;Mol. Cell. Pharmacol.,2009 3. Zappavigna, S., Cossu, A.M., Grimaldi, A., Bocchetti, M., Ferraro, G.A., Nicoletti, G.F., Filosa, R., and Caraglia, M. (2020). Anti-Inflammatory Drugs as Anticancer Agents. Int. J. Mol. Sci., 21. 4. Management of glioblastoma: State of the art and future directions;Tan;CA Cancer J. Clin.,2020 5. Challenges to curing primary brain tumors;Aldape;Nat. Rev. Clin. Oncol.,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|